If the FDA approves nipocalimab, the long-term data could form part of J&J’s pitch for the gMG market. The labels for ...

Participants will review the latest clinical evidence surrounding neonatal Fc receptor (FcRn) inhibitors, including their role in addressing underlying disease processes and supporting long-term ...

Immunovant shunts next-gen FcRn drug ahead of batoclimab in race ... The decision reflects evidence batoclimab lowers albumin and, in doing so, affects cholesterol. Believing it has mitigated ...

Batoclimab targets and inhibits FcRn, reducing harmful IgG antibodies, offering potential for IgG-mediated autoimmune diseases. The treatment is being studied for TED, generalized myasthenia gravis, ...